Sahajanand Medical Technologies Ltd. Share Price

Arvind Limited's Greenfield Garment Manufacturing Facility

Arvind Limited's inaugurated by Prime Minister Shri Narendra Modi state-of-the-art garment manufacturing facility in Varanasi, UƩar Pradesh, in the presence of Smt. Anandiben Patel, Hon’ble Governor of Uttar Pradesh, Shri Yogi Adityanath, Hon'ble Chief Minister of Uttar Pradesh, senior government officials and industry leaders. Developed with an investment of approximately ₹150 crore, the facility is Arvind's first manufacturing unit in Uttaar Pradesh. Spread across a sprawling landscape of 5.5 acres and with a total built up area of approximately 65,000 sq. ft, the plant has a revenue potentential of Rs 250 Cr and is expected to generate employment for over 1,000 people, predominantly women, and manufacture essential knitwear products using advanced automated sewing technologies. Opinion : This news will have positive impact on the stock price. Disclaimer : I do not hold this stock. This is not a buy,sell or hold recommendation.

See More

Sahajanand Medical Technologies LtdLIST AT NEARLY 8% PREMIUM

Shares of Sahajanand Medical Technologies made a strong debut on the stock exchanges on October 23, listing at a premium of nearly 8% over the initial public offering price of Rs 344 per share. The stock opened at Rs 371.15, registering a gain of 7.89% over the issue price. The stock's listing performance exceeded grey market expectations. According to Investorgain, Sahajanand Medical Technologies shares were commanding a grey market premium that indicated an estimated listing gain of around 5% on the morning of October 23. Investor demand for the IPO was led by qualified institutional buyers, whose allotted portion was subscribed 34.70 times. The non-institutional investor category received 14.64 times subscription, while the retail investor segment was subscribed 3.03 times. Headquartered in Mumbai, Sahajanand Medical Technologies develops medical devices for cardiovascular and vascular interventions. Its product portfolio includes coronary stents, coronary balloons and structural heart devices, such as transcatheter aortic valve implantation systems and occluders. The company also manufactures renal stents under its own brand and offers peripheral drug-coated balloons. Its products are designed for use in procedures to treat cardiovascular diseases and other vascular disorders.

See More